Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Executive Vice President | September 01, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date September 01, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 193,646 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Gift · Disposed 80,000 · Balance 193,646 F1: Represents a gift to trust for the benefit of certain family members whereby reporting person does not serve as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a gift to trust for the benefit of certain family members whereby reporting person does not serve as trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 2, 2026 21:03 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GiftClass A Common Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-060179 · wk-form4_1788383011.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,646 F1 · kind: Represents a gift to trust for the benefit of certain family members whereby reporting person does not serve as trustee. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:41 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GiftClass A Common Stock | 152,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-058918 · wk-form4_1787690491.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,646 F1 · kind: Represents a gift to trust for the benefit of certain family members whereby reporting person does not serve as trustee. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 38,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · derivative · entry 15 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,389 Underlying: Class A Common Stock · 38,195 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F9 · derivative.exercise_date: On March 4, 2024, the reporting person was granted 152,778 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F9 · derivative.expiration_date: On March 4, 2024, the reporting person was granted 152,778 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 19,136 | $13.30 | $254,508.80 |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 10 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 426,072 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 38,195 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 9 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 445,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 397,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · derivative · entry 14 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 397,554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.expiration_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 24,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · derivative · entry 13 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,774 Underlying: Class A Common Stock · 24,258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F8 · derivative.exercise_date: On March 3, 2025, the reporting person was granted 97,032 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F8 · derivative.expiration_date: On March 3, 2025, the reporting person was granted 97,032 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 49,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · derivative · entry 12 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,695 Underlying: Class A Common Stock · 49,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 198,777 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 198,777 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 39,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · derivative · entry 11 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 39,252 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: On March 4, 2022, the reporting person was granted 157,005 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On March 4, 2022, the reporting person was granted 157,005 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 199,175 | $13.31 | $2,651,019.25 |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 8 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407,013 F5 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 397,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 7 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 606,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 12,154 | $13.31 | $161,769.74 |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 6 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,634 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 24,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 5 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 24,897 | $13.31 | $331,379.07 |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 4 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,530 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 49,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 19,945 | $13.31 | $265,467.95 |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,733 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 39,252 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015238 · wk-form4_1772746263.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 65,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-013878 · wk-form4_1772573190.xml · derivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,359 Underlying: Class A Common Stock · 65,359 shares Expires not disclosed F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period. F4 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 65,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-013878 · wk-form4_1772573190.xml · derivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,359 Underlying: Class A Common Stock · 65,359 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 20:38 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionStock Option · Derivative | 175,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001628280-25-041033 · wk-form4_1755895080.xml · derivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,480 Underlying: Class A Common Stock · 175,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are fully vested. F2 · derivative.expiration_date: These options are fully vested. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 20:38 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 279,244 | $9.38 | $2,619,308.72 |
DisclosureSEC source: 0001628280-25-041033 · wk-form4_1755895080.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,426 F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.40 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 20:38 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 175,000 | $2.75 | $481,250.00 |
DisclosureSEC source: 0001628280-25-041033 · wk-form4_1755895080.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 20:38 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 33,436 | $9.05 | $302,595.80 |
DisclosureSEC source: 0001723128-25-000048 · wk-form4_1755117489.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,670 F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.05 to $9.07 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 125,000 | $8.89 | $1,111,250.00 |
DisclosureSEC source: 0001628280-25-011310 · wk-form4_1741382302.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,106 F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.70 to $9.00 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 38,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · derivative · entry 14 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,582 Underlying: Class A Common Stock · 38,194 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F11 · derivative.exercise_date: On March 4, 2024, the Reporting Person was granted 152,778 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F11 · derivative.expiration_date: On March 4, 2024, the Reporting Person was granted 152,778 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 19,537 | $8.84 | $172,707.08 |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · nonDerivative · entry 8 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,106 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 38,194 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · nonDerivative · entry 7 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 97,032 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · derivative · entry 13 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,033 Underlying: Class A Common Stock · 97,032 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F10 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2026. F10 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2026. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 194,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · derivative · entry 12 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,064 Underlying: Class A Common Stock · 194,064 shares Expires not disclosed F8 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F9 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 97,032 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2028, the last day of the performance period. F9 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 97,032 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2028, the last day of the performance period. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 157,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · derivative · entry 11 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 157,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.expiration_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 49,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · derivative · entry 10 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,389 Underlying: Class A Common Stock · 49,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 198,777 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 198,777 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 39,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · derivative · entry 9 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,252 Underlying: Class A Common Stock · 39,251 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: On March 3, 2022, the reporting person was granted 157,005 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On March 3, 2022, the reporting person was granted 157,005 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 80,309 | $8.76 | $703,506.84 |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · nonDerivative · entry 6 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,449 F5 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 157,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · nonDerivative · entry 5 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 476,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 25,419 | $8.76 | $222,670.44 |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · nonDerivative · entry 4 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,753 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 49,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · nonDerivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 20,077 | $8.76 | $175,874.52 |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,478 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 39,251 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010718 · wk-form4_1741223923.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:03 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 31,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010118 · wk-form4_1741133025.xml · derivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 31,371 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 125,483 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 125,483 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:03 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 11,737 | $8.67 | $101,759.79 |
DisclosureSEC source: 0001628280-25-010118 · wk-form4_1741133025.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,304 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:03 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 31,371 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010118 · wk-form4_1741133025.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 20:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 40,225 | $7.85 | $315,766.25 |
DisclosureSEC source: 0001628280-24-037559 · wk-form4_1723839496.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,670 F2 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.80 per share to $7.92 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 22,486 | $7.81 | $175,615.66 |
DisclosureSEC source: 0001628280-24-037559 · wk-form4_1723839496.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,895 F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.80 per share to $7.84 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 305,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008951 · wk-form4_1709674816.xml · derivative · entry 11 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,556 Underlying: Class A Common Stock · 305,556 shares Expires not disclosed F8 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F9 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 152,778 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period. F9 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 152,778 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 152,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008951 · wk-form4_1709674816.xml · derivative · entry 10 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,778 Underlying: Class A Common Stock · 152,778 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 4, 2025. F7 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 4, 2025. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 49,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008951 · wk-form4_1709674816.xml · derivative · entry 9 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,083 Underlying: Class A Common Stock · 49,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 198,777 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 198,777 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 39,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008951 · wk-form4_1709674816.xml · derivative · entry 8 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,503 Underlying: Class A Common Stock · 39,251 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F5 · derivative.exercise_date: On March 3, 2022, the reporting person was granted 157,005 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On March 3, 2022, the reporting person was granted 157,005 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 24,897 | $5.47 | $136,186.59 |
DisclosureSEC source: 0001628280-24-008951 · wk-form4_1709674816.xml · nonDerivative · entry 6 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,381 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 49,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-008951 · wk-form4_1709674816.xml · nonDerivative · entry 5 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 19,665 | $5.47 | $107,567.55 |
DisclosureSEC source: 0001628280-24-008951 · wk-form4_1709674816.xml · nonDerivative · entry 4 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,584 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.